PWLE Forum: ALS Clinical Outcome Assessment- Initial Public Discussion

The Critical Path Institute (C-Path) and Food and Drug Administration (FDA) provided an overview of patient-focused drug development, endpoints that inform regulatory decision making, a summary of work to date on concepts and tools, and next steps for engaging with people with lived experience.

To submit written feedback or ask questions about the COA, please email the Critical Path Institute- Rare Neurodegenerative Diseases, use "COA Feedback" in the Subject line. Submitted questions will be used to help guide the discussion for future public sessions.